Tag: Gout
Transient Increase Seen in CV Events Following Gout Flare
Among gout patients experiencing cardiovascular events, odds of gout flare higher in preceding 0 to 60 and 61 to 120 days
Urate-Lowering Treatments Compared for Gout
More participants receiving low-dose benzbromarone than low-dose febuxostat achieved serum urate target at 12 weeks
Worldwide Burden of Gout Increased From 1990 to 2017
Men had higher global point prevalence estimates for gout; prevalence higher in older age groups
ACR Updates Guideline for Management of Gout
ULT strongly recommended for tophaceous gout, radiographic damage due to gout, gout flares
Amlodipine Better BP Drug for Lower Long-Term Risk for Gout
Compared with chlorthalidone and lisinopril, amlodipine associated with lower risk for gout
Gout Incidence Down With SGLT2 Inhibitors in Type 2 Diabetes
Gout incidence rate significantly reduced with SGLT2 inhibitor versus GLP-1 receptor agonist
Four Modifiable Risk Factors Tied to Hyperuricemia
Public health efforts to promote healthy diet and prevent obesity might cut gout cases, authors say
Gout May Up Risk for Progression of Chronic Kidney Disease
Gout more than doubles the risk for end-stage kidney disease
Opioids Commonly Prescribed in Emergency Department for Gout
Diabetes, polyarticular gout, prior opioid use tied to increased risk for opioid prescription at discharge
Gout Linked to Increased Risk for Venous Thromboembolism
Venous thromboembolism risk similar for patients with gout regardless of urate-lowering therapy
